Scienture divests IPS and Bonum to Tollo for $5M note; focuses on Specialty Pharma

Scienture Holdings, Inc.

Total consideration is $5M in a promissory note bearing interest at prime rate, maturing June 30, 2030.
Closing expected June 30, 2025; Tollo must pay 20% of future equity proceeds toward the note.
CEO Suren Ajjarapu and President Prashant Patel have beneficial interest in buyer Tollo (related party).
Proceeds will fund high-growth product development at Scienture, LLC subsidiary.
Divestiture includes legacy Healthcare IT (IPS, Bonum, Softell) to streamline operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.